Drug Profile

Autologous chondrocyte implant - TETEC

Alternative Names: Matrix-assisted autologous chondrocyte transplantation - TETEC; N3D; NOVOCART^® 3D Plus; NOVOCART® Inject

Latest Information Update: 04 Dec 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator TETEC
Developer Aesculap Biologics; TETEC
Class Cell therapies
Mechanism of Action Cartilage replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Cartilage disorders

Most Recent Events

29 Sep 2020 Phase-III development for Cartilage disorders is ongoing in USA (NCT03219307)
30 Nov 2018 Aesculap Biologics initiates enrolment in a phase III trial for Cartilage disorders in USA (NCT03219307)
17 Jul 2017 Aesculap Biologics plans a phase III trial, an extension trial of AAG-G-H-1220, for Cartilage disorders in USA (NCT03219307)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com